Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Icagen implements DMC's recommendations in phase III study of ICA-17043

Aug. 9, 2006

Targeting 5-HT6 receptors with E-6837: a novel approach for the management of obesity

Aug. 8, 2006

Novel CB1 receptor antagonist shows antiobesity potential in vivo

Aug. 8, 2006

Recent patents describe novel agents for obesity, hypercholesterolemia, etc.

Aug. 8, 2006

New antidiabetic agents disclosed in recent patent literature

Aug. 8, 2006

Sitagliptin begins phase III diabetes studies in Japan

Aug. 8, 2006

Competact receives European approval for diabetes

Aug. 8, 2006

Successful end of phase II meeting for cetilistat

Aug. 8, 2006

Preterm birth prevention study of Prochieve completes enrollment

Aug. 7, 2006

Alliance updates Oxygent progression for postoperative ileus

Aug. 3, 2006

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 18, 2026.
ASGCT 2026: Directed evolution in gene therapy
BioWorld
Directed evolution has become a central pillar in gene therapy. This engineering strategy enables the generation of more efficient variants of genetic editors and...
ASGCT 2026: Uncovering the mechanisms of AAV toxicity
BioWorld
Gene therapies rely on vectors to reach the target tissue where they act, such as adeno-associated viruses (AAVs) or lipid nanoparticles (LNPs), among other...
Fosun secures rights to Aribio’s AR-1001 in potential $4.7B deal
BioWorld
Shanghai Fosun Pharmaceutical (Group) Co. Ltd. is paying $60 million up front for an option to secure exclusive rights to Aribio Co. Ltd.’s oral phase III-stage...
Biogen AD drug shows tau, cognition benefit, despite trial miss
BioWorld
Biogen Inc. has decided to advance diranersen (BIIB-080) into registrational trials for early Alzheimer’s disease, even though the antisense oligonucleotide...